| abstract |
A method for producing a dry vaccine powder formulation that can be used for nasal delivery. The method includes the step of producing a liquid formulation containing one or more antigens, such as pathogens or components thereof, together with one or more substances. Freeze-dry the liquid vaccine formulation to produce a powder. The powder can contain microparticles, is stable at room temperature, and if the antigen is an influenza virus, the powder has high HA potency. After freeze-drying, the powder is mixed with one or more excipients to form a dry vaccine powder formulation. [Selection figure] None |